The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders

Main Article Content

Yu.M. Stepanov
N.S. Fedorova
E.V. Zyhalo


Background. The article deals with the problem of small intestinal bacterial overgrowth (SIBO) syndrome in patients with chronic inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS), and ways to correct it. The purpose was to determine the incidence of SIBO in Crohn’s disease (CD), ulcerative colitis (UC) and IBS with diarrhea and to evaluate the efficiency of rifaximin in the correction of small intestinal microflora in patients with these pathologies. Materials and methods. A study was conducted in 62 patients with chronic IBD and IBS (27 — with UC, 13 — with CD and 22 — with IBS) to detect the presence of SIBO by performing a hydrogen breath test (HBT) with glucose loading. All patients of the study group with SIBO received Alfa Normix at a dose of 1200 mg per day for 10 days as a part of comprehensive therapy. The efficiency of therapy was determined by the dynamics of HBT on day 10 and 30 of observation. Results. SIBO was detected in 39 patients of the general group, of them 24 (61.5 %) patients suffered from chronic IBD, 15 (38.5 %) people had IBS with diarrhea. Patients with UC (15 persons; 62.5 %) were predominant in the group of chronic IBD with SIBO, compared to those with CD (9 persons; 37.5 %). HBT performed 10 days after the start of rifaximin treatment (Alfa Normix) in 24 patients with chronic IBD and 15 persons with IBS with the presence of SIBO was negative in 28 (70.9 %) and remained positive in 11 people (29.1 %). The same result was noted after 30 days: HBT was negative in 26 (66.7 %) patients, and positive — in 13 (33.3 %). So, the elimination of SIBO was achieved in 70.9 % of patients when using Alfa Normix. Conclusions. Most patients in the study group (60 % with chronic IBD and 68.1 % with IBS with diarrhea) had SIBO. The intestinal antiseptic rifaximin (Alfa Normix) has been shown to be highly effective in correcting SIBO in UC, CD and IBS.

Article Details

How to Cite
Stepanov, Y., Fedorova, N., & Zyhalo, E. (2019). The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders. GASTROENTEROLOGY, 53(4), 246–251.
Original Researches


Safarpour AR, Hosseini SV, Mehrabani D. Epidemiology of inflammatory bowel diseases in iran and Asia; a mini review. Iran J Med Sci. 2013 Jun;38(2 Suppl):140-9.

Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010 Jun 28;16(24):2978-90. doi: 10.3748/wjg.v16.i24.2978.

Rana SV, Bhardwaj SB. Small intestinal bacterial overgrowth. Scand J Gastroenterol. 2008;43(9):1030-7. doi: 10.1080/00365520801947074.

Ford AC, Chey WD, Talley NJ, Malhotra A, Spiegel BM, Moayyedi P. Yield of diagnostic tests for celiac disease in subjects with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med. 2009 Apr 13;169(7):651-8. doi: 10.1001/archinternmed.2009.22.

Perederiy VG, Kozlov VO, Syzenko GK. The syndrome of bacterial overgrowth: from diagnosing to treatment. Modern Gastroenterology. 2011;(57):124-129. (in Russian).

Krajicek EJ, Hansel SL. Small Intestinal Bacterial Overgrowth: A Primary Care Review. Mayo Clin Proc. 2016 Dec;91(12):1828-1833. doi: 10.1016/j.mayocp.2016.07.025.

Svintsitskyy AS, Revenok KM, Liva YY. Role of small intestinal bacterial overgrowth syndrome in the development and progression of nonalcoholic fatty liver disease. Praktykujuchyj likar. 2014;(3):83-85. (in Ukrainian).

Zvyagintseva TD, Chernobay AI. Bacterial overgrowth syndrome: modern approaches to treatment. Family medicine. 2013;(48):31-38. (in Russian).

Plotnikova EIu, Krasnova MV, Baranova EN. Respiratory hydrogen tests in the diagnosis of bacterial overgrowth syndrome. In: Dignostika zabolevanii zheludochno-kishechnogo trakta po vydykhaemomu vozdukhu: sbornik nauchnykh statei [Diagnosis of diseases of the gastrointestinal tract by exhaled air: a collection of scientific articles]. Saint-Petersburg: 2012. 64-70 pp. (in Russian).

Perederiy VG, Tkach SM, Syzenko GK, Shvets OV. Clinical use of hydrogen breath tests in gastroenterology. Modern Gastroenterology. 2010;(54):26-33. (in Russian).

Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy in patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

Koo HL, Dupont HL, Huang DB. The role of rifaximin in the treatment and prevention of traveler's diarrhea. Ther Clin Risk Manag. 2009;5:841-8. doi: 10.2147/tcrm.s4442.

Tkach SM, Cheverda TL, Onishuk LA, Kaznadiy AV. The efficacy of rifaximin in syndrome of intestinal bacterial overgrowth. Modern Gastroenterology. 2015;(81):23-29. (in Russian).

DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers` diarrhea. Ann Intern Med. 2005 May 17;142(10):805-12. doi: 10.7326/0003-4819-142-10-200505170-00005.

Ponziani FR, Zocco MA, D'Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017 Jul 7;23(25):4491-4499. doi: 10.3748/wjg.v23.i25.4491.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>